Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites

Japanese Journal of Clinical Oncology

Volumn 40, Issue 12, 2010, Pages 1184-1188

  Soeda, Atsuko ^a,b   Morita Hoshi, Yuriko ^a   Kaida, Miho ^a   Wakeda, Takako ^a   Yamaki, Yuni ^a   Kojima, Yasushi ^a   Ueno, Hideki ^a   Kondo, Shunsuke ^a   Morizane, Chigusa ^a   Ikeda, Masafumi ^a   Okusaka, Takuji ^a   Heike, Yuji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Gemcitabine; Incomplete Freund's adjuvant; Inflammation; Ulcer; WT 1 peptide vaccine

Indexed keywords

ARGINYLMETHIONYLPHENYLALANYLPROLYLASPARAGINYLALANYLPROLYLTYROSYLLEUCINE; CANCER VACCINE; CYSTEINYLTYROSYLTHREONYLTRYPTOPHYLASPARAGINYLGLUTAMINYLMETHIONYLASPARAGINYLLEUCINE; GEMCITABINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG; WT1 PROTEIN;

AGED; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; BLOOD TOXICITY; BONE METASTASIS; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HYPOALBUMINEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE NODULE; INJECTION SITE PRURITUS; INJECTION SITE ULCER; LOCAL SKIN REACTION; LONG TERM CARE; LUNG METASTASIS; NAUSEA; SYMPTOM; T LYMPHOCYTE; VACCINATION; VOMITING;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DERMATITIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; INJECTIONS, INTRADERMAL; LIVER NEOPLASMS; LYMPHOCYTES; NUCLEAR PROTEINS; PALLIATIVE CARE; RADIOTHERAPY, ADJUVANT; SKIN;

EID: 78649594148     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq112     Document Type: Article

References (15)

1. Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, et al. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 2009;39:797-806.
2. *24 phenotype undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2005;36:803-11.
3. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001;19: 3836-47.
4. Smith JW, II, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 2003;21:1562-73.
5. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004;22:4474-85.
6. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007;13:6386-95.
7. Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 2008;26:4973-80.
8. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/2-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009;15:1443-51.
9. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94.
10. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351:2295-301.
11. Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007;119:1076-82.
12. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008;198:650-8.
13. Halperin W, Weiss WI, Altman R, Diamond MA, Black KJ, Iaci AW, et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/ 75: report of a study and review of the literature. Am J Public Health 1979;69:1247-51.
14. Warrell MJ, Suntharasamai P, Nicholson KG, Warrell DA, Chanthavanich P, Viravan C, et al. Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens. Lancet 1984;1:874-6.
15. Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guerin. J Infect Dis 1996;174:113-9.